Basilea Pharma awarded USD 7.3 million additional CARB-X funding to develop new drug candidate from a novel class of antibiotics: Allschwil, Switzerland Thursday, December 26, 202 ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

The initial use of combination antimicrobial therapy for gram-negative infections is usually ... risk of superinfection with more-resistant bacteria or fungi. There are no clinical data that ...

Additional funding awarded following successful drug candidate nominationUSD 7.3 million to support progression of antibiotic BAL2420 (LptA inhibitor) towards first-in-human clinical studies Ad hoc ...

Nevertheless, we would recommend it only in cases of severe infection by MDR gram-negative bacteria as a second-line drug at appropriate dosages and with monitoring of renal function and ...

In the realm of orthopedic medicine, the challenge of managing infected bone defects (IBDs) has persisted as a significant hurdle. The advent of ...

In the realm of orthopedic medicine, the challenge of managing infected bone defects (IBDs) has persisted as a significant ...

You will be redirected to our submission process. The most common quorum sensing (QS) system in Gram-negative bacteria occurs via N-acyl homoserine lactone (AHLs) signals. An archetypical system ...

Researchers from Northern Arizona University published a study showing the health risks of multi-drug-resistant bacteria.

Within the human digestive tract are trillions of bacteria from thousands of different species. These bacteria form ...

Shiseido is working to future proof its suncare using molecules extracted from the cell membrane of bacteria to filter ... It aims to address negative emotions and their impact on the skin.